CDC25C and prostate adenocarcinoma: Our analysis revealed that CDC25 family members acted as patient risk factors in the TCGA cohort, that is, patients with high expression of CDC25 family members exhibited poorer survival in 11 cancer types (adrenocortical carcinoma (ACC), BRCA, KICH, KIRC, kidney renal papillary cell carcinoma (KIRP), brain lower grade glioma (LGG), LIHC, mesothelioma (MESO), PRAD, SARC, and UCEC) (hazard ratio (HR) > 1, p < 0.05).